Disease Diagnosis TRIZ Cases

A diagnostic strip containing monoclonal antibodies detects eosinophil-derived neurotoxin for rapid asthma identification.

Anti-RAN protein antibodies target homopolymeric repeat regions to enable immunoassay detection of pathogenic proteins in biological samples.

Quantitative biomarker measurement differentiates stable from unstable moderate early-onset preeclampsia cases.

Serum ELISA detects anti-TUBB3 autoantibodies, enabling non-invasive ovarian cancer diagnosis and drug resistance prediction without tissue biopsies.

A biomarker panel quantifies fucosylated proteins and soluble receptors to distinguish aggressive from non-aggressive prostate cancer, reducing false positives.

EpCAM-based enrichment isolates rare CTCs for precise PSMA quantification to predict therapy resistance.

Measuring calcium isotope ratios in urine eliminates radiation exposure and baseline measurements while maintaining diagnostic accuracy.

A cyclic citrullinated peptide forms an anti-CCP antibody-peptide complex to detect antibodies, resolving low specificity in rheumatoid arthritis diagnosis.

Cancer cells bind platelet factor 4 to detect heparin-induced thrombocytopenia antibodies, replacing fresh platelets for reliable diagnosis.

A solid support immobilizes tagged antigens to capture autoantibodies from clinical samples for parallel analysis.

Measuring tank-treading motion proportions in red blood cells provides a sensitive marker for deformability assessment.

A multi-protein biomarker composition detects specific expression levels to diagnose pre-eclampsia.

Mass spectrometry detects dengue virus NS1 protein with an immobilized ligand, resolving the trade-off between detection sensitivity and method complexity.

A metabolic biomarker panel measures amino acids, acylcarnitines, and biogenic amines to assess kidney health.

An assembly combines gel electrophoresis with immunological detection to quantify specific lipoprotein particles in bodily fluids.

Autonomously nourishing living organisms enable reliable chemical substance screening without external feeding infrastructure.

Direct plasminogen measurement detects fibrinolytic insufficiency without complex cascade reactions.

A diagnostic method measuring Angiotensin-1-7 levels to predict clinical complications in viral respiratory diseases.

In vitro cytokine abundance measurement differentiates bipolar disorder from major depressive disorder using specific biomarker concentrations.

Using sCD127 as a biomarker resolves the trade-off between assessment accuracy and clinical practicality, replacing complex scoring systems.

A rapid diagnostic test strip uses rare-earth particles to detect multiple analytes simultaneously on a single line.

Engineered targeting molecules isolate microbial components directly from blood, bypassing culture steps to resolve detection delays in septic patients.

Analyzing NS1-lipoprotein complexes provides early dengue detection and severity prognosis, addressing delayed diagnosis limitations.

LC-MS/MS quantification of di-sialylated hemopexin glycoforms replaces invasive biopsy to monitor liver fibrosis progression and treatment efficacy.

Analyzing non-rare cells detects rare circulating tumor cells, reducing false positives and cell loss from physical enrichment.

A monoclonal antibody targets the C-terminal neoepitope of cross-linked PIIINP to enable precise immunoassay detection.

Measuring circulating Trop-2 protein in serum provides high sensitivity and specificity for detecting aggressive breast cancer stages.

RT-QuIC assay analyzes detergent-soluble fractions to differentiate Parkinson disease from dementia with Lewy bodies using molecular evidence.

A biomarker assessment method identifies patient responsiveness to combination therapies using PD-L1 and tumor mutational burden levels.

Multi-color antibody panel identifies pediatric solid tumors and immune cells, resolving diagnostic accuracy versus procedural complexity.

Pro-Endothelin-1 biomarker predicts peak oxygen consumption, replacing complex gas exchange equipment with a simple blood assay for accurate risk assessment.

A diagnostic method detects cardiac troponin and BNP-type peptide concentrations in patient samples to identify necrosis causes.

A lateral flow assay device uses fluorescently labeled antibodies to detect PF4/heparin complexes in fluid samples.

Measuring soluble CD146 in embryo culture media predicts implantation potential, reducing multiple pregnancy risks.

In vitro prediction method assesses patient immune cell reactions to reduce adverse responses and optimize outcomes without complex HLA matching.

Measuring specific biomarkers like C-C motif chemokine 23 enables early acute kidney injury detection before serum creatinine rises.

Assessing urinary vitamin D binding protein levels identifies patients at risk of renal failure after contrast media exposure.

Adjusting nanoparticle size and detection wavelengths reduces lipid interference while improving measurement precision and linearity.

Detecting mitochondrial polypeptides in bodily samples identifies cardiac ischemia before cell death occurs.

Combines seed amplification assays with oligomer-specific ELISAs to detect and quantify alpha-synuclein aggregates in cerebrospinal fluid.

Segmenting intermediate monocytes via flow cytometry improves detection precision while reducing method complexity compared to traditional scans.

Machine learning algorithms process flow cytometry data to distinguish immunophenotypes and predict hematological disease types.

Quantitative IgG N-glycan analysis via ultraperformance liquid chromatography enables cardiovascular disease risk assessment.

Analyzing gut microbiota metabolites like imidazole propionate resolves diagnostic reliability gaps for metabolic disorders.

Measuring IL-33 and HMGB1 resolves the contradiction between biomarker reliability and injury assessment precision.

Immunofluorescent detection of AR-V7 protein in circulating tumor cells guides taxane therapy selection for metastatic castration-resistant prostate cancer patients.

A 3D organoid assay isolates invasive epithelial cell populations through competitive invasion behavior.